Search results
38 Results for 'Vaccines'
- Technologies (7)
- Collaborations (0)
- Team (0)
- News (24)
- Events (0)
- Multimedia (7)
- Publications (0)
- Jobs (0)
Technologies 7
-
Cellular “Backpacks” to Slow Tumor Growth
Macrophages are the body’s multipurpose defense agents, patrolling for pathogens and engulfing cellular debris, foreign substances, microbes, and even cancer cells. But cancerous tumors have evolved an insidious defense mechanism: they can switch arriving macrophages from an anti-cancer state to a pro-cancer state, in which they help promote the tumor’s growth. As a result, attempts... -
DNA Nanotechnology Tools: From Design to Applications
A suite of diverse, multifunctional DNA nanotechnological tools with unique capabilities and potential for a broad range of clinical and biomedical research areas. Our DNA nanotechnology devices were engineered to overcome specific bottlenecks in the development of new therapies and diagnostics, and to help further our understanding of molecular structures. -
OMNIVAX: Broadly Deployable Infection Vaccine Platform
OMNIVAX is an immuno-material-based vaccine platform technology able to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial threats. Its modular approach enables the rapid creation of vaccines for pathogens using known and unknown antigens. Current approaches include vaccines against some viral diseases. -
Bone Marrow-Like Scaffolds for Accelerating Immune Reconstitution
An implantable bone marrow cryogel to accelerate the full reconstitution of the immune system, including T cell immunity, in patients that received chemotherapy and a bone marrow transplant. This could provide an off-the-shelf, material-based solution for patients with severe blood disorders whose immunity is recovering only slowly after treatment. -
eRNA: Controlled Enzymatic RNA Oligonucleotide Synthesis
Synthetic RNA oligonucleotides designed as specific successions of the four nucleobases A, U, G, and C that mimic naturally occurring RNA species are the key components of diverse RNA-based therapies. These include RNA therapeutics that can partially or completely turn off the expression of disease-causing genes (antisense and interfering RNAs), help replace or supplement dysfunctional... -
Implantable Cancer Vaccine
The implantable cancer vaccine is an aspirin-sized disc that is implanted under the skin and serves as an artificial lymph node, recruiting and training a patient's own immune cells to find and kill their cancer cells. It was validated in a Phase I clinical trial at the Wyss Institute, and is currently being developed by Novartis to treat melanoma.
News 24
Multimedia 7
-
Video/AnimationThe Game-Changing Potential of mRNA VaccinesPromising mRNA vaccines years ago emerged from early-stage development, only to stall before proving themselves in clinical trials. Pushed by pandemic urgency across the notorious “Valley of Death,” this platform vastly exceeded expectations and is now poised to transform the vaccine R&D landscape. During the early months of the historic rollout of COVID-19 vaccines, Sabin’s... -
Video/AnimationOMNIVAX: Infection Vaccine PlatformThis video explains how OMNIVAX – an immuno-material-based vaccine technology can be used to rapidly create injectable vaccines against diverse viral and bacterial pathogens, and how the platform is used by the team to develop a vaccine against recurring urinary tract infections (UTIs) in their lead human application. Credit: Wyss Institute at Harvard University. -
Video/AnimationBeating Back the CoronavirusWhen the coronavirus pandemic forced Harvard University to ramp down almost all on-site operations, members of the Wyss Institute community refocused their teams, and formed new ones, in order to fight COVID-19 on its multiple fronts. These efforts include building new pieces of personal protective equipment that were delivered to frontline healthcare workers, developing new... -
Audio/PodcastDisruptive: Cancer Vaccine and Immuno-MaterialsImmunotherapy – treatment that uses the body’s own immune system to help fight disease – has groundbreaking and life-saving implications. In an effort to make immunotherapy more effective, Wyss Institute researchers are developing new immuno-materials, which help modulate immune cells to treat or diagnose disease. In this episode of Disruptive, Dave Mooney, Wyss Core Faculty... -
Video/AnimationWyss Focus: Immuno-MaterialsWyss Core Faculty, Dave Mooney, explains our new Immuno-Materials Focus Area, which adds a new dimension to immunotherapy in that it harnesses materials to make treatments more efficient and effective. These material-based systems are capable of modulating immune cells and releasing them into the body where they can treat diseases. -
Audio/PodcastDisruptive: Cancer Vaccine & Hydrogel Drug DeliveryIn this episode of Disruptive, Wyss Founding Core Faculty Member Dave Mooney discusses programmable nanomaterials approaches to fighting disease. Mooney explains how a cancer vaccine, developed by his team and currently in a clinical trial at the Dana-Farber Cancer Institute, can train one’s own immune system to target specific cancer cells. He also describes the...